Savara (SVRA) Change in Cash (2010 - 2026)
Savara (SVRA) posted quarterly Change in Cash of $5.6 million for Q1 2026, up 26.72% year-over-year from $4.4 million in Q1 2025, and down 66.8% quarter-over-quarter from $16.9 million in Q4 2025.
Analysis
Savara (SVRA) Change in Cash (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Change in Cash for 17 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 26.72% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $19.2 million (up 594.15% YoY), while the FY2025 annual figure was $18.1 million, up 257.56% from the prior year.
- Change in Cash slipped to $5.6 million in Q1 2026 per SVRA's latest filing, from $16.9 million in the prior quarter.
- Across five years, Change in Cash topped out at $45.2 million in Q1 2022 and bottomed at -$67.7 million in Q4 2022.
- Historically, Change in Cash has averaged $281117.6 across 5 years, with a median of -$1.1 million in 2023.
- On a YoY basis, Change in Cash climbed as much as 510.18% in 2022 and fell as far as 533.86% in 2022.
- Savara's Change in Cash stood at -$67.7 million in 2022, then jumped by 98.37% to -$1.1 million in 2023, then tumbled by 470.05% to -$6.3 million in 2024, then surged by 368.34% to $16.9 million in 2025, then slumped by 66.8% to $5.6 million in 2026.
- Business Quant data shows SVRA's Change in Cash at $5.6 million in Q1 2026, $16.9 million in Q4 2025, and -$1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | 3.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.01 Mn |
| Mar 31, 2026 | 5.61 Mn |
| Dec 31, 2025 | 16.90 Mn |
| Sep 30, 2025 | -1.16 Mn |
| Jun 30, 2025 | -2.12 Mn |
| Mar 31, 2025 | 4.43 Mn |
| Dec 31, 2024 | -6.30 Mn |
| Sep 30, 2024 | -2.44 Mn |
| Jun 30, 2024 | 7.08 Mn |
| Mar 31, 2024 | -9.80 Mn |
| Dec 31, 2023 | -1.11 Mn |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | -11.24 Mn |
| Mar 31, 2023 | -18.12 Mn |
| Dec 31, 2022 | -67.74 Mn |
| Sep 30, 2022 | 24.69 Mn |
| Jun 30, 2022 | 15.93 Mn |
| Mar 31, 2022 | 45.22 Mn |
| Dec 31, 2021 | -10.69 Mn |
| Sep 30, 2021 | 4.05 Mn |